Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on:
BTIG just reiterated Buy /
$70 PT after
$RPRX +
$JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where
$SYRE is positioning.
Why it matters:
Big Pharma doubling down on multi-pathway biology
Direct sympathy to
$SYRE’s SPY120/130/230 combo platform
DUET data from
$JNJ later this year = potential sentiment catalyst
Pipeline timeline:
2Q26: SPY001 (anti-CD47) PoC readout
2026: SPY002 (TL1A) + SPY003 (IL-23) data follow
2027: Full Phase 2 combo data (SKYLINE)
Underrated angle:
TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next.
More shots on goal:
3Q26: SPY072 (RA)
4Q26: axSpA + PsA data
Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up.
Market hasn’t fully priced this in yet. Stay alert.
